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patients with acute or sub-acute DVT with or without PTE without any signiﬁcant
complication.
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Differences in Patients’ Selection and Outcomes of SilverHawk Atherectomy
versus Laser Atherectomy in Treating In-Stent Restenosis of the Femoropopliteal
Arteries: A Retrospective Analysis from a Single Center
Nicolas W. Shammas1, Gail A. shammas1, Michael Jerin1
1Midwest Cardiovascular Research Foundation, Davenport, IA
Background: Treatment of in-stent restenosis (ISR) of the femoropopliteal (FP) artery
remains a challenge to the endovascular specialist. Silverhawk (SA) and excimer laser
atherectomy (ELA) use different mechanisms in restenotic tissue reduction. We report
data on FP ISR treatment with SA and ELA in an unselected cohort of patients treated
at a single center.
Methods: Demographic, clinical, angiographic and procedural data was collected on
all patients that underwent SA and ELA (laser Elite 83.3%, Booster or Tandem
16.7%) for FP ISR from January 2005 until June 2010. Major adverse events and one-
year target lesion revascularization (TLR) were obtained by review of medical records
and phone calls. Univariate analysis was used to compare the 2 groups. Cox
Regression analysis for TLR over time was performed to adjust for differences
between the 2 cohorts and modeled for the following variables: SA vs. ELA, lesion
length, TASC D lesions (versus A-C), diabetes, age, gender and bail out stenting.
Results: 81 consecutive patients (41 SA, 40 ELA) were included in the analysis. ELA
was utilized more frequently in longer lesions, subacute presentation, TASC D
lesions, and in patients with more angiographic thrombus. Percent stenosis post ELA
was 56.6%  0.7% vs SA 33.8%  7.5% (p¼0.015). Percent stenosis post ELA was
56.6%  0.7% vs SA 33.8%  7.5% (p¼0.015). Final angiographic success (< 30%
residual narrowing post ﬁnal treatment) was similar between ELA and SA respectively
(92.5% vs. 100%, p¼0.12). Embolic ﬁlter protection was used equally in both
modalities (ELA 57.5% vs. SA 56.1%, p¼1.00). DE requiring treatment occurred in
2.5% in ELA vs 7.3% of SA (p¼0.2). There were no device related complications.
The primary outcome of TLR at 1 year occurred in 48.7% and 31.7% of ELA and SA
respectively (p¼0.171). ELA had a steeper failure rate than SA in the ﬁrst 6 months
post treatment and to a lesser extent after 6 months, whereas SA showed lesser TLR
initially but a higher TLR after 6 months. Cox Regression analysis showed that SA
was a predictor of TLR at 1 year.
Conclusions: Both SA and ELA continued to have high TLR rates in treating ISR of
the FP arteries. SA appears to be a predictor of TLR at 1 year.
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Pooled Analysis of the CONFIRM Registries: Outcomes in Critical Limb
Ischemia Patients Treated for Peripheral Arterial Disease with Orbital
Atherectomy
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Background: Peripheral arterial disease (PAD) that results in critical limb
ischemia (CLI) is associated with signiﬁcant morbidity and mortality. Within the
ﬁrst year of diagnosis 25% of CLI patients will die and 30% will undergo
amputation. In this patient population that includes advanced age, diabetes, and renal
insufﬁciency, intra-arterial calcium is typically a predictor of poor endovascular
treatment success.
Methods: 3135 patients undergoing orbital atherectomy (OA) for treatment of PAD
were enrolled on an "all-comers" basis in 3 consecutive patient registries. All patients
were treated with the Orbital Atherectomy System manufactured by Cardiovascular
Systems, Inc. (St. Paul, MN). CONFIRM I evaluated the Diamondback360,
CONFIRM II evaluated the Predator360, and CONFIRM III evaluated Diamond-
back360, Predator360, and Stealth360. An analysis of the CLI data as it pertains to
the correlation of plaque morphology/calciﬁcation to the outcomes within the CLI
patient population after OA treatment was performed using the CONFIRM registry
series.
Results: 44% of the patients in the CONFIRM series had CLI (Rutherford
Categories 4-6) with documented lesion morphology, of which 87% presented with
moderate/severely calciﬁed lesions. There was no signiﬁcant difference in the
percentage of dissection (9.1% vs 12.2%), perforation (0.9% vs 0.6%), slow ﬂow
(5.7% vs 4.7%), closure (1.6% vs 1.2%), or spasm (6.4% vs 9.3%), in CLI
patients with moderate/severely calciﬁed lesions vs those without moderate/
severely calciﬁed lesions, respectively. Patients with CLI with moderate/severe
calcium had a lower rate of embolism (1.7% vs 5.2%, p¼0.01) and lower rate of
thrombus (0.9% vs 4.4%, p¼0.001) compared to patients without moderate/severely
calciﬁed lesions.
Conclusions: The majority of the CLI patients in this study had lesions with moderate
to severe calciﬁcation, yet the occurrence of adverse events was low after treatment
with orbital atherectomy. Orbital atherectomy is a safe tool for restoring blood ﬂow in
the lower extremities of CLI patients regardless of arterial calcium burden.JACC Vol 62/18/Suppl B j October 27–November 1, 2013 j TCT AbstrTCT-541
Preliminary results from the Jetstream navitus system Endovascular Therapy
post-market (JET) registry
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Background: Treatment of complex lesions in the femoropopliteal (FP) artery
including long, occluded, diffuse, thrombotic or calciﬁed lesions carries an increased
risk of major adverse events (MAE), reduced patency at 1 year and recurrent target
lesion revascularization (TLR). The post market multicenter JET registry is currently
evaluating the Jetstream atherectomy system in treating denovo or non stent restenotic
lesions of the FP artery.
Methods: JET is a multi-center, open-label, non-randomized registry in up to 75 sites
with a target enrolment of 500 patients, Rutherford category 1-3 and with denovo or non
stent restenotic FP lesions 4 cm in length and 70% in severity. Lesions with in-stent
restenosis, or crossed via a subintimal approach or treated within 1 month prior to index
procedure are excluded. The primary endpoint is binary stenosis at 12 months as deﬁned
by duplex ultrasound derived systolic velocity ratio>2.5. Secondary endpoints include
procedural success as deﬁned by successful revascularization of target vessel deﬁned as
 30% residual diameter stenosis following atherectomy  adjunctive therapy,
improvement in ankle-brachial index through 12 months compared to pre-procedural
baseline and MAE through 30 days. MAE is deﬁned as amputation, death, TLR, target
vessel revascularization, myocardial infarction, or angiographic distal embolization
requiring separate intervention or hospitalization. Index angiogram and duplex ultra-
sound assessment of binary stenosis will be evaluated by core laboratory.
Results: Preliminary results from the ﬁrst 60 patients enrolled in the JET registry are
as follows: mean age 65.5 yrs, males 68.3%, diabetics 50%, smoking history 63.4%,
hypertension 87.8%, Preprocedure ABI 0.68, non stent restenotic lesions 78.8%,
lesion length 174 mm, reference diameter 5.7 mm, pretreatment stenosis 90%, post
Jetstream stenosis 45% and post adjunctive treatment 9%. The JetStream total run was
3.52 min, adjunctive stenting was 30.9%. Distal embolic protection was used in only
3.6% of patients. There were no in-hospital complications.
Conclusions: Jetstream atherectomy of FP lesions appears to have a high procedural
success and reduced in-hospital complications.
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False Lumen Thrombus Formation and Long-Term Outcomes in Type B Aortic
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Background: The prognostic signiﬁcance of false lumen thrombus formation in type
B aortic dissection remains unclear.
Methods: Aortic dissection cases were identiﬁed from the Kaiser Permanente-
Registry of Aortic Dissections (KP-RAD). This is a population-based registry that
captures consecutive cases of aortic dissections among the approximately 3,000,000
health plan members in Southern California. The presence of any false lumen
thrombus by CT angiography during follow-up period was categorized as partial or
complete thrombus. The primary outcome was a composite of aorta related mortality,
myocardial infarction, stroke, aortic rupture, or dissection extension.
Results: There were 384 patients with type B aortic dissection, of which 293 had
a patent false lumen and 91 had partial or complete thrombosis. The mean age (SD)
for subjects with a patent false lumen was 69 (16) and 64 (13) with presence of false
lumen thrombus (p<0.001). There was no difference between groups for gender
(p¼0.20). The median follow up was 4 years with maximum follow-up of 7 years. The
cumulative incidence rate by presence or absence of false lumen thrombus was 30.0%
vs. 17.2% respectively (p¼0.01) (see ﬁgure).acts/POSTER/Endovascular Intervention B163
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in long-term aorta related morbidity and mortality. These ﬁndings may have
implications on risk stratiﬁcation, frequency of surveillance imaging, and future
treatments.
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Covered Endovascular Reconstruction of Aortic Bifurcation or CERAB-
technique for treating extensive aortoiliac occlusive disease.
Peter Goverde1, Michel Reijnen2
1ZNA Stuivenberg Hospital, Antwerp, Belgium, 2Rijnstate Hospital, Arhnem,
Netherlands
Background: We developed the Covered Endovascular Reconstruction of Aortic
Bifurcation or CERAB-technique for extensive and/or recurrent aortoiliac occlusive
disease using V12 covered balloon expandable stents (Atrium Maquet Getinge Europe
BV) to rebuild the aortic bifurcation.
Methods: Endovascular bifemoral recanalisation of the aortoiliac axes,; placement
and expansion of a 12 mm V12 Large Diameter in the distal aorta (9 Fr). Pick up of
the already expanded V12 stent with an large balloon (adapted to the aortic diameter).
The balloon is so positioned that the distal marker is about 15 mm proximal to the
distal stent margin. After positioning and expansion, the distal stent part becomes
funnel-shaped. Two iliac covered stent-grafts are then placed in this segment, in
a "kissing-stent" conﬁguration and inﬂated. Both stents are now making a very tight
combination with the aortic stent, as were they moulded together, simulating a new
bifurcation
Results: Two-centre prospective, non-randomised, follow-up study. We treated now
70 patients with acute, chronic or recurrent aortoiliac occlusive disease. Technical
success rate up till now was almost 95%. Follow-up 52 – 1 months. 5 patients died of
non-interventional causes . Five patients re-occluded, mainly due to progressive distal
peripheral disease. They received successfully thrombolysis and treatment of the
outﬂow problems. The other patients showed no complications.
Conclusions: Covered Endovascular Reconstruction of Aortic Bifurcation or
CERAB is safe and feasible and can be performed completely percutaneous. A
larger population, longer follow-up, further haemodynamic investigation is needed
Distal peripheral outﬂow needs to be sufﬁcient enough. It can be combined as
a "hybrid" procedure. CERAB can be used for the treatment of recurrent or in-stent
disease It is even feasible to treat lesion that extend to the iuxta and/or supral renal
aortic region
TCT-544
The Potential Role of Statin in Patients with Critical Limb Ischemia.
Atsushi Tosaka1, Yoshimitsu Soga2, Osamu Iida3, Masato Nakamura4
1Kawakita General Hospital, Tokyo, Tokyo, 2Kokura Memorial Hospital, Kitakyushu,
Japan, 3Kansai Rosai Hospital, Amagasaki, Hyogo, 4Toho University Ohashi Medical
Center, Tokyo, Japan
Background: Revascularization is the optimal treatment to avoid major amputation
for critical limb ischemia (CLI) patients. Although previous studies report that statin
administration is associated with a reduced risk for cardiovascular events, the efﬁcacy
for CLI patients is unclear. In this study, we aimed to compare the outcomes in CLI
patients with statin administration and without statin administration after endovascular
therapy (EVT).
Methods: This study is a subanalysis from Endovascular Treatment for Infra-inguinal
Vessel, in patients with critical limb ischemia, - A Prospective, Multi-center, 12 month
follow-up Registry in Japan: Olive Registry. From November 2009 to December
2011, a total of 310 patients with CLI who underwent EVT for infrainguinal artery
disease were enrolled. The outcome measures were limb salvage and major adverse
limb event (MALE). MALE was deﬁned as major amputation or major reintervention
including surgical procedure.
Results: The mean follow-up period was 294  138 days. Sixty-ﬁve percent were
male, 26% had statin administration. Rutherford class IV was found in 38 patients, V
in 217 patients and VI in 55 patients. Kaplan-Meier survival curve showed that the
limb salvage rate at one year was 97.3% in the statin group, 89.7% in the without
statin group (P¼0.03). In adjusted model, limb salvage rate and freedom from MALE
were statistically higher in the statin group (P<0.01).
Conclusions: Statin administration after infrainguinal angioplasty for CLI patients
improved limb salvage rate and freedom from MALE.B164 JACC Vol 62/18/Suppl B j October 27–NTCT-545
The AURORAA registry : 1 year reults using interwoven nitinol stents for
extensive distal femoropopliteal occlusive disease.
Peter Goverde1, Katrien Lauwers2, Sven Vercauteren2
1ZNA Stuivenberg Hospital, Antwerp, Belgium, 2Vascular Clinic ZNA, Antwerp,
Belgium
Background: In the endovascular treatment of extensive disease in the distal super-
ﬁcial femoral and popliteal level, you can encounter ﬂow limiting problems, where
stent placement is needed after balloon angioplasty. At the moment most of the
standard bare nitinol stents will have difﬁculties in these areas. With the introduction
of the Supera stent (IDEV Technologies, Inc., Texas, US) we may have an answer in
treating those problematic lesions
Methods: Because of the Superas new design; with 6 interwoven nitinol wires, it has
extraordinary characteristics : very ﬂexible, kink, fracture and crush resistant together
with great radial force. We have treated more than 100 patients with extensive distal
femoropopliteal disease (TASC II C & D) with heavy calciﬁcations, occlusions,
recurrent disease, stent fractures etc. These lesions, that not responded to balloon
angioplasty and that needed stent placement, were al treated with placement of Supera
stents.
Results: Results of the single centre prospective AURORAA registry : Follow up
done by ultrasound. Five patients died of non-interventional causes.. Six months
primary patency was more then 90%. Twelve months primary patency was around
81%. We observed further more no stent fractures or ﬂow limiting kinking in this very
difﬁcult "to stent" area (distal superﬁcial femoral artery & popliteal artery). Average
lesion length: 14 cm; average stent length : 18 cm. Technical success rate :96 %
Conclusions: The Supera stent can be a solution when the use of a "classic" nitinol
stent is not indicated or favourable , especially in the femoropoliteal area. It has very
good patency rates, despite the very difﬁcult region to treat This self expandable stent
system can be a necessary complement in your tool box due to its special
characteristics
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Safety and feasibility of one day discharge after endovascular revascularization
of lower extremities in elderly.
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Poland, 8Clinical Associate Professor of Medicine at UTHSC in San Antonio, San
Antonio, TX
Background: The elderly have a high prevalence of peripheral arterial disease (PAD)
and it seems that they may be less suitable for a one day discharge after endovascular
revascularization (ER) mainly due to a higher ratio in hemorrhage complications.
Therefore we sought to evaluate whether the advantages of one day discharge after ER
on lower extremities can be safely extended for the elderly.
Methods: Between January 2008 and June 2012, 455 ER were performed on lower
extremities with Bivalirudin as an anticoagulant. The decision of deployment the
vascular closure device (VCD) was left to the operator discretion. Patients 70 years old
and older were included to the study group (n¼235). The rest of the patients created
the control group (n¼220). The follow up was done at 24 hours and 30 days afterovember 1, 2013 j TCT Abstracts/POSTER/Endovascular Intervention
